Ensign Peak Advisors Inc Has $1.20 Million Stake in Guardant Health, Inc. (NASDAQ:GH)

Ensign Peak Advisors Inc grew its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 4.5% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 41,450 shares of the company’s stock after buying an additional 1,800 shares during the period. Ensign Peak Advisors Inc’s holdings in Guardant Health were worth $1,197,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. Canton Hathaway LLC acquired a new stake in Guardant Health during the second quarter worth $59,000. Byrne Asset Management LLC acquired a new stake in shares of Guardant Health during the 2nd quarter valued at about $77,000. Manchester Capital Management LLC bought a new stake in Guardant Health in the first quarter valued at about $57,000. EntryPoint Capital LLC acquired a new position in Guardant Health in the first quarter worth about $75,000. Finally, Fullcircle Wealth LLC bought a new position in Guardant Health during the second quarter worth about $211,000. Institutional investors own 92.60% of the company’s stock.

Guardant Health Trading Up 0.7 %

NASDAQ GH opened at $22.88 on Friday. Guardant Health, Inc. has a 52 week low of $15.81 and a 52 week high of $37.04. The company has a debt-to-equity ratio of 16.70, a quick ratio of 6.07 and a current ratio of 6.40. The stock’s 50 day moving average price is $27.92 and its two-hundred day moving average price is $25.18. The stock has a market capitalization of $2.80 billion, a price-to-earnings ratio of -5.84 and a beta of 1.11.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.10). The business had revenue of $177.24 million during the quarter, compared to the consensus estimate of $162.59 million. Guardant Health had a negative return on equity of 418.21% and a negative net margin of 76.23%. The business’s revenue for the quarter was up 29.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.67) EPS. As a group, analysts anticipate that Guardant Health, Inc. will post -3.31 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on GH shares. Guggenheim upgraded Guardant Health from a “neutral” rating to a “buy” rating and set a $36.00 price objective on the stock in a research note on Friday, June 28th. Jefferies Financial Group began coverage on Guardant Health in a report on Monday, June 3rd. They set a “buy” rating and a $32.00 price objective for the company. Piper Sandler increased their target price on shares of Guardant Health from $30.00 to $34.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. The Goldman Sachs Group lifted their price target on shares of Guardant Health from $28.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, July 17th. Finally, JPMorgan Chase & Co. boosted their target price on Guardant Health from $45.00 to $48.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $39.67.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.